These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 35118)

  • 1. Relationship between the B-mitten EEG pattern and tardive dyskinesia. A pilot control study.
    Wegner JT; Struve FA; Kantor JS; Kane JM
    Arch Gen Psychiatry; 1979 May; 36(5):599-603. PubMed ID: 35118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An electroencephalographic study of psychiatric inpatients with antipsychotic-induced tardive dyskinesia.
    Koshino Y; Hiramatsu H; Isaki K; Yamaguchi N
    Clin Electroencephalogr; 1986 Jan; 17(1):30-5. PubMed ID: 2869843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of mitten patterns to neuroleptic drug induced dyskinesias in psychiatric patients: early investigative findings.
    Struve FA; Kane JM; Wegner JT; Kantor J
    Clin Electroencephalogr; 1979 Jul; 10(3):151-63. PubMed ID: 38924
    [No Abstract]   [Full Text] [Related]  

  • 4. The B-mitten EEG pattern and tardive dyskinesia: a possible association.
    Wegner JT; Struve FA; Kane JM
    Am J Psychiatry; 1977 Oct; 134(10):1143-5. PubMed ID: 900271
    [No Abstract]   [Full Text] [Related]  

  • 5. Tardive dyskinesia.
    Jeste DV; Caligiuri MP
    Schizophr Bull; 1993; 19(2):303-15. PubMed ID: 8100643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early course of new-onset tardive dyskinesia in older patients.
    Lacro JP; Gilbert PL; Paulsen JS; Fell R; Bailey A; Juels C; Caligiuri M; McAdams LA; Harris MJ; Jeste DV
    Psychopharmacol Bull; 1994; 30(2):187-91. PubMed ID: 7831454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic medication facilitates the natural occurrence of tardive dyskinesia. A critical review.
    Driesens F
    Acta Psychiatr Belg; 1988; 88(3):195-205. PubMed ID: 2906780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amisulpride-induced tardive dyskinesia.
    Fountoulakis KN; Panagiotidis P; Siamouli M; Kantartzis S; Mavridis T; Iacovides A; Kaprinis G
    Schizophr Res; 2006 Dec; 88(1-3):232-4. PubMed ID: 16963229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
    Chakos MH; Alvir JM; Woerner MG; Koreen A; Geisler S; Mayerhoff D; Sobel S; Kane JM; Borenstein M; Lieberman JA
    Arch Gen Psychiatry; 1996 Apr; 53(4):313-9. PubMed ID: 8634009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia and psychotropic drug history.
    Simpson GM; Varga E; Lee JH; Zoubok B
    Psychopharmacology (Berl); 1978 Jul; 58(2):117-24. PubMed ID: 28544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.
    Preskorn S; Flynn A; Macaluso M
    J Psychiatr Pract; 2015 Sep; 21(5):359-69. PubMed ID: 26348804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic implications of the B-mitten EEG pattern: relationship to primary and secondary affective dysregulation.
    Struve FA; Klein DF
    Biol Psychiatry; 1976 Oct; 11(5):599-611. PubMed ID: 971451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anomalous dominance and persistent tardive dyskinesia.
    Barr WB; Mukherjee S; Degreef G; Caracci G
    Biol Psychiatry; 1989 Apr; 25(7):826-34. PubMed ID: 2566333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of tardive dyskinesia: implications for assessment and treatment.
    Valdovinos MG; Roberts C; Kennedy CH
    J Appl Behav Anal; 2005; 38(2):239-42. PubMed ID: 16033170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.